Publications

Incidence of SARS-CoV-2 infection and clinical characteristics in children and young people living with HIV in Europe

2022

Authors: Chappell E, Bamford A, Berzosa Sanchez A, Goetghebuer T, Marques L, Naver L, NogueraJulian A, Talarek E, Plotnikova Y, Samarina A, Ene L, Spolou V, Collins I

Presented at: International Workshop on HIV & Pediatrics 2022

Read more

Population pharmacokinetics of unbound and total plasma dolutegravir concentrations in children ≥ 12 years old: A pharmacokinetic sub-study of the SMILE trial-PENTA17-ANRS 152

2022

Authors: Abdalla S, Compagnucci A, Riault Y, Cressey T, Saidi Y, Chan M, Coelho A, Nolan A, Chalermpantmetagul S, Amuge P, Musiime V, Violari A, Cotton M, Volokha A, Bologna R, Pavia Ruz N, Morkunaite G, Giaquinto C, Tréluyer JM, Zheng Y, Bamford A, Ramos Amador J, Hirt D

Presented at: International Workshop on HIV and Pediatrics

Read more

Voluntary Consent to Research on HIV-infected Children in the CHAPAS-4 and ODYSSEY HIV Clinical Trials

2022

Authors: Makumbi S, Bajunirwe F, Ford D, Turkova A, Lugemwa A, Musiime V, Gibb D, Tamwesigire K.I

Presented at: International Workshop on HIV & Pediatrics 2022

Read More

Detection of Potential Arbovirus Infections and Pregnancy Complications in Pregnant Women in Jamaica Using a Smartphone App (ZIKApp): Pilot Evaluation Study

2022

Authors: Ruiz-Burga E, Bruijning-Verhagen P, Palmer P, Sandcroft A, Fernandes G, de Hoog M, Bryan L, Pierre R, Bailey H, Giaquinto C, Thorne C, Christie CDC, ZIKAction Consortium

Published in: JMIR Formative Research

What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies

2022

Authors:Jacobs TG, Schouwenburg S, Penazzato M, Archary M, Ruel TD, van den Anker J, Burger DM, Cressey TR, Abrams EJ, Lyall H, Bekker A, Colbers A; Penta Clinical Pharmacology Working Group; PADO-HIV 5 participants.

Published in: The Lancet

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

2022

Authors: Turkova A, Waalewijn H, Chan M, Bollen P, Bwakura-Dangarembizi M, Kekitiinwa A, Cotton M, Lugemwa A, Variava E, Ahimbisibwe MG, Srirompotong U, Mumbiro V,Amuge P, Zuidewind P, Ali S, Kityo C,Archary M, Ferrand R, Violari A, Gibb D,Burger D, Ford D, Colbers A, on behalf of the ODYSSEY Trial Team

Published in: The Lancet

Controlling SARS-CoV-2 in schools using repetitive testing strategies

2022

Authors: Torneri A, Willem L, Colizza V, Kremer C, Meuris C, Darcis G, Hens N, Libin PJK.

Published in: eLife

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age

2022

Authors: Cohen-Stavi CJ, Magen O, Barda N, Yaron S, Peretz A, Netzer D, Giaquinto C, Judd A, Leibovici L, Hernán MA, Lipsitch M, Reis BY, Balicer RD, Dagan N.

Published in: The New England Journal of Medicine

Severity and Outcomes of Dengue in Hospitalized Jamaican Children in 2018–2019 During an Epidemic Surge in the Americas

2022

Authors: A Lue, M Richards-Dawson, G Gordon-Strachan, S Kodilinye, J Dunkley Thompson, T James-Powell, C Pryce, C Mears, J Anzinger, K Webster-Kerr and C Christie

Published in: Frontiers in Medicine

 

Seasonal patterns of SARS-CoV-2 transmission in secondary schools: a modelling study

2022

Authors: Pham TM, Westerhof I, Bootsma MCJ, Kretzschmar ME, Rozhnova G, Bruijning-Verhagen P.

Published in: MedRxiv

Omicron Neutralizing and Anti-SARS-CoV-2 S-RBD Antibodies in Naïve and Convalescent Populations After Homologous and Heterologous Boosting With an mRNA Vaccine

2022

Authors: Pagliari M, Mazzetto E, Gastaldelli M, Bortolami A, Donà D, Padoan A, Di Chiara C, Pezzani MD, Cosma C, Napolitan A, Quaranta EG, Giussani E, Fusaro A, Pascarella M, Aita A, Liberati C, Lorusso A, Monne I, De Rossi A, Basso D, Porru S, Ricci A, Terregino C, Plebani M, Tacconelli E*, Giaquinto C*, Bonfante F*.

Published in: Lancet Preprints

Preliminary Evidence on Pulmonary Function after Asymptomatic and Mild COVID-19 in Children

2022

Authors: C. D. Chiara, S. Carraro, S. Zanconato, S. Cozzani, E. Baraldi et al.

Published in: National Library of Medicine

Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections – a survival analysis

2022

Authors: Hussey H, Davies MA, Heekes A, Williamson C, Valley-Omar Z, Hardie D, Korsman S, Doolabh D, Preiser W, Maponga T, Iranzadeh A, Wasserman S, Boloko L, Symons G, Raubenheimer P, Parker A, Schrueder N, Solomon W, Rousseau P, Wolter N, Jassat W, Cohen C, Lessells R, Wilkinson RJ, Boulle A, Hsiao NY.

Published in: International Journal of Infectious Diseases

Case numbers of acute hepatitis of unknown aetiology among children in 24 countries up to 18 April 2022 compared to the previous 5 years

2022

Authors: Beek JV, Fraaij PL, Giaquinto C, Shingadia D,  Horby P, Indolfi G, Koopmans M, Acute hepatitis study group

Published in: Eurosurveillance

Editorial: Modelling COVID-19 in school settings to evaluate prevention and control protocols

2022

Authors: Colosi E, Bassignana G, Barrat A, Colizza V.

Published in: Anaesthesia Critical Care & Pain Medicine

Screening and vaccination against COVID-19 to minimise school closure: a modelling study

2022

Authors: Colosi E, Bassignana G, Contreras DA, Poirier C, Boëlle PY, Cauchemez S, Yazdanpanah Y, Lina B, Fontanet A, Barrat A, Colizza V

Published in: The Lancet

Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive Therapy

2022

Authors: Ruggiero A, Pascucci G.R, Cotugno N, Domínguez-Rodríguez S, Rinaldi S, Tagarro A, Rojo P, Foster C, Bamford A, De Rossi A, Nastouli E, Klein N, Morrocchi E, Fatou B, Smolen K.K, Ozonoff A, Di Pastena M, Luzuriaga K, Steen H, Giaquinto C, Goulder P, Rossi P, Levy O, Pahwa S, Palma P, the EPIICAL Consortium

Published in: Frontiers in Immunology 

Early Use of Sotrovimab in Children:A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2

2022

Authors: Di Chiara C, Mengato D, De Pieri M, Longo G, Benetti E, Venturini F, Giaquinto C and Donà D.

Published in: Children

The subphenotypes of early-treated children living with HIV-1

2022

Authors: S Domínguez-Rodríguez, A Tagarro, C Foster, P Palma, N Cotugno, AD Rossi, A Dalzini, SG. Pahwa, E Nastouli, K Gärtner, AG Marcelin, P Rossi, C Giaquinto, P Rojo

Presented at: CROI 2022

Read more

2-year outcome of early treated infants in Sub-Saharan Africa

2022

Authors: A Tagarro, S Domínguez-Rodríguez, L Kuhn, T Nhampossa, K Otwombe, AJv Rensburg, N Klein, MG Lain, AI. Maiga, C Brehin, C Giaquinto, P Rossi, P Rojo

Presented at: CROI 2022

Read more

Birth outcomes following prenatal exposure to dolutegravir: the DOLOMITE-EPPICC study

2022

Authors: C Thorne, K Aebi-Popp, L Ene, M Floridia, AM Gamell, M Illan, H Peters, A Samarina, L Ragone, C Giaquinto, V Vannappagari

Presented at: CROI 2022

Read more

Respiratory Syncytial Virus–Associated Hospital Admissions and Bed Days in Children <5 Years of Age in 7 European Countries

2022

Authors: X Wang, Y Li, L.V Fernandez, A.C Teirlinck, T Lehtonen, M.V Wijhe, L Stona, M Bangert, R.M Reeves, H Bøås, M.V Boven, T Heikkinen, C.K Johannesen, E Baraldi, D Donà, S Tong, H Campbell, Respiratory Syncytial Virus Consortium in Europe (RESCEU) Investigators

Published in: The Journal of Infectious Diseases

ZIKAction paediatric registry: maternal characteristics and clinical, radiological, and follow-up features of children born with congenital zika infection in brazil

2022

Authors: B.L de Almeida, I.C de Siqueira, M.L.C Lage, L.S Lopes, A.L de Carvalho, M.M de Lima, M.d.F.N Goes, M.N Crispim, B.G.G Costa, C Giaquinto, G Fernandes, E Ruiz-Burga, C Thorne on belhaf of Zikaction consortium

Presented at: WSPID 2022

Read more

Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial

2022

Authors: R.M. Turner, A Turkova, C.L. Moore, A Bamford, M Archary, L.N. Barlow-Mosha, M.F. Cotton, T.R. Cressey, E Kaudha, A Lugemwa, H Lyall, H.A. Mujuru, V Mulenga, V Musiime, P Rojo, G Tudor-Williams, S.B. Welch, D.M. Gibb, D Ford, I.R. White & and the ODYSSEY Trial Team

Published in: BMC Medical Research Methodology

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

2022

Authors: H Waalewijn, M.K Chan, P.D.J Bollen, H.A Mujuru, S Makumbi, A.R Kekitiinwa, E Kaudha, T Sarfati, G Musoro, A Nanduudu, A Lugemwa, P Amuge, C.L Moore, P Rojo, C Giaquinto, A Colbers, D.M Gibb, D Ford, A Turkova, D.M Burger

Published in: The Lancet

Antenatal Seroprevalence of Zika and Chikungunya Viruses, Kingston Metropolitan Area, Jamaica, 2017–2019

2022

Authors: J.J. Anzinger, C.D. Mears, A.E. Ades, K Francis, Y Phillips, Y.E. Leys, M.J. Spyer, D Brown, A.M.B.d Filippis, E Nastouli, T Byrne, H Bailey, P Palmer, L Bryan, K Webster-Kerr, C Giaquinto, C Thorne, C.D.C. Christie, and on behalf of the ZIKAction Consortium

Published in: Emerging Infectious Diseases Journal

 

Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease

2022

Authors: L. Bosa, C. Di Chiara, P. Gaio, C. Cosma, A. Padoan et al.

Published in: Frontiers in Pediatrics

Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice

2022

Authors: F Malik, V Chulanov, N Pimenov, A Fomicheva, R Lundin, N Levina, C Thorne, A Turkova, G Indofi

Published in: The Journal of viral elimination

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

2021

Authors: A Turkova, E White, HA. Mujuru, AR. Kekitiinwa, CM. Kityo, A Violari, A Lugemwa, TR. Cressey, P Musoke, E Variava, MF. Cotton, M Archary, et al for the ODYSSEY Trial Team

Published in: New England Journal of Medicine

Size of HIV-1 reservoir is associated with telomere shortening and immunosenescence in early-treated European children with perinatally acquired HIV-1

2021

Authors: A Dalzini, G Ballin, S Dominguez-Rodriguez, P Rojo , M.R Petrara, C Foster, N Cotugno, A Ruggiero, E Nastouli, N Klein, S Rinaldi, S Pahwa, P Rossi, C Giaquinto, P Palma , A De Rossi1, and on behalf of EPIICAL Consortium

Published in: Journal of the International AIDS Society

Dolutegravir-based ART is superior to standard of care ART in young children <14kg living with HIV

2021

Authors: Kaudha E on behalf of the ODYSSEY trial

Presented at: PEPFAR Uganda Science Summit

Read more

Diaskin and tuberculin skin test as tuberculosis diagnostics in Russian children: comparative observational study

2021

Authors: Fritschi N, Gureva T, Eliseev P, Crichton S ,Intira Jeannie Collins IJ, Turkova T, Mariandyshev A, Ritz N

Presented at: The 52nd Union World Conference On Lung Health 2021

Read more

Characterisation of the HIV proviral and inducible reservoir in well- suppressed children on long-term ART

2021

Authors: Gärtner K, Byott M, Heaney J, Pagliuzza A, Spyer M.J Frampton D, Rossi A.D, Palmas P, Giaquinto C, Conejo P.R, Foster C,  Rossi P, Klein N, Chomont N, Nastouli E, for the EPIICAL consortium

Presented at: Keystone symposia on molecular and cellular biology

Read more

Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial

2021

Authors: Hill L.F, Clements M.N, Turner M.A, Donà D, Lutsar I, Jacqz-Aigrain E, Heath P.T, Roilides E, Rawcliffe L, Alonso-Diaz C, Baraldi E, Dotta A, Ilmoja M, Mahaveer A, Metsvaht T, Mitsiakos G,  Papaevangelou V, Sarafidis K, Walker A.S, Sharland M, on behalf of the NeoVanc Consortium

Published in: The Lancet

Dolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV (combined results of the main trial and the ‘under 14kg’ cohort)

2021

Authors: Anna Turkova on behalf of the ODYSSEY trial team

Presented at: CHIVA 2021

Read more

Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the main ODYSSEY trial (≥14kg)

2021

Authors: White E and Kityo C on behalf of the ODYSSEY trial team

Presented at: CHIVA 2021

Read More

Causes of Microcephaly in the Zika Era in Argentina: A Retrospective Study

2021

Authors: G Berberian, R Bologna, MG Pérez, A Mangano, PhD, M Costa, MSc, S Calligaris, MA Morales, C Rugilo, E Ruiz-Burga, C Thorne

Published in: Sage Journals

Aetiology of acute respiratory infection in preschool children requiring hospitalisation in Europe—results from the PED-MERMAIDS multicentre case–control study

2021

Authors: MK Vasconcelos, K Loens, L Sigfrid, E Iosifidis, C Epalza, D Donà, V Matheeussen, S Papachristou, E Roilides, M Gijon, P Rojo, C Minotti, L Da Dalt, S Islam, J Jarvis, A Syggelou, M Tsolia, MN Nyang’wa, S Keers, H Renk, AL Gemmel, C D’Amore, MC degli Atti, CRT Sánchez, F Martinón-Torres, S Burokienė, T Goetghebuer, V Spoulou, A Riordan, C Calvo, D Gkentzi, M Hufnagel,

No age-related difference in dolutegravir metabolic glucuronidation ratio in children between 3 months and 18 years old in the ODYSSEY trial

2021

Authors: T.G Jacobs, A. Colbers, H. Waalewijn, P. Amuge, D. Bbuye, E. Kaudha, A. Nanduudu, S. Makumbi, L. Atwine, S. Mudzingwa, K. Nathoo, J. Hakim, A. Liberty, A.J. Van Rensburg, M. Archary, D.M Gibb, D. Ford, A. Turkova, D.M Burger, ODYSSEY trial team

Published in: IAS 2021

 

Abstract

Background: ODYSSEY and IMPAACT-P1093 found lower and more variable dolutegravir (DTG) exposure in children compared to adults based on mg/kg dose.

Effect of dolutegravir on folate and vitamin B12 status among HIV- infected children and adolescents in the ODYSSEY trial

2021

Authors: L. Barlow-Mosha, G. Ahimbisibwe, E. Chappell, P.M. Amuge, A. Nanduudu, E. Kaudha, T. Amukele, D. Balamusani, B. Kafufu, A. Nimwesiga, C. Kityo, A.R Kekitiinwa, R. Namwanje, G. Kasangaki, A. Mulindwa, G.A. Muzorah, D. Bbuye, M. Nolan, C. Giaquinto, D.M Gibb, D. Ford, P. Musoke, A. Turkova, The ODYSSEY Trial Team

Presented at: International workshop on HIV pediatrics 2021

Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial

2021

Authors: E White, A Turkova, HA Mujuru, I Nankya, B Wynne, S Ali, A Kekitiinwa, A Lugemwa, E Kaudha, A Liberty, H Cassim, M Archary, M Cotton, L Barlow-Mosha, TR Cressey, C Ngampiyasakul, U Srirompotong, O Behuhuma, Y Saidi, A Bamford, R Kobbe, P Rojo, C Giaquinto, DM Gibb, D Ford on behalf of the ODYSSEY trial team

Published in: International Workshop on HIV pediatrics

 

Dolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV (combined results of the main trial and the ‘under 14kg’ cohort)

2021

Authors: Turkova A on behalf of the ODYSSEY trial team     

Presented at: CHIVA 2021

Read More

Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial

2021

Authors: A Turkova, A Kekitiinwa, E White, V Mumbiro, E Khauda, A Liberty, E Dobbels, GM Ahimbisibwe, T Moloantoa, L Atwine, S Kanjanavanit, NR Mosia, T Puthanakit, T Smit, R Kobbe, C Fortuny, E Chidziva, RC Kyambadde, D Bbuye, T Sarfati, A Coelho, Y Saïdi, A Lugemwa, N Klein, M Bwakura-Dangarembizi, C Kityo, M Cotton, C Giaquinto, P Rojo, DM Gibb, D Ford, the ODYSSEY trial team

Published in: IAS 2021

 

Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trial

2021

Authors: Violari A, Kekitiinwa A, White E, Mumbiro V, Rutebarika D, Dobbels E, Kataike H, Moloantoa T, Atwine L, Nazzinda R, Mbabazi R, Kanjanavanit S, Mosia N, Na-Rajsimax S, Techakunakorn P, Nakabuye S, Puthanakit T, Smit T, Kobbe R, Fortuny C, Chidziva E, Nansamba W, Kakayi B, Bbuye D, Sarfati T, Shakeshaft C, Coelho A, Saïdi Y, Lugemwa A, Klein N, Mujuru H, Bwakura- Dangarembizi M, Musiime V,

Effect of dolutegravir on folate and vitamin B12 status among HIV- infected children and adolescents in the ODYSSEY trial

2021

Authors: L. Barlow-Mosha, G. Ahimbisibwe, E. Chappell, P.M. Amuge, A. Nanduudu, E. Kaudha, T. Amukele, D. Balamusani, B. Kafufu, A. Nimwesiga, C. Kityo, A.R Kekitiinwa, R. Namwanje, G. Kasangaki, A. Mulindwa, G.A. Muzorah, D. Bbuye, M. Nolan, C. Giaquinto, D.M Gibb, D. Ford, P. Musoke, A. Turkova, The ODYSSEY Trial Team

Published in: IAS 2021

 

Abstract

Background: Neural tube defects (NTDs) are known to be associated with maternal folate and vitamin B12 deficiency,

Dolutegravir-Based ART is Superior to Standard of Care in Young Children Living With HIV

2021

Authors: P Amuge on behalf of the ODYSSEY trial team

Published in: International workshop on HIV pediatrics 2021

 

Abstract

Background: ODYSSEY, a multi-country randomised trial, demonstrated superior treatment efficacy for dolutegravir (DTG) plus two NRTIs versus standard-ofcare (SOC) in 707 children ≥14kg (median age 12 years) starting first- or second-line ART.

Weight Gain in Children and Adolescents on Dolutegravir vs Standard-of-Care in the ODYSSEY Trial

2021

Authors: Mujuru H , Lugemwa A, Puthanakit T, Amuge P, Kityo C, Compagnucci A, Variava E, Kekitiinwa A, Musiime V, BarlowMosha L, Ngampiyaskul C, Zuidewind P, Tumusiime J, Mngqbisa R, Kaudha E, Behuhuma N, Kataike H, Musoro G, Nandudu A, Bwakura M, Ahimbisibwe G, Ounchanum P, Mulindwa A, Nazzinda R, Ssenyonga M, Kanjanavanit S, Nathoo K, Makumbi S, Danaviah S, Nakabuye S, Chalermpantmetagul S, Rutebarika D, Nalusiba S,

A randomised comparison of DTG-based ART vs Standard of Care in infants and young children living with HIV weighing 3 to 14kg: results from the ODYSSEY trial

2021

Authors: A Lugemwa, H Mujuru, B Wynne, A Violari, AR Kekitiinwa, CM Kity, M Archary, E Variava, T Sarfati, C Shakeshaft, R Turner, K Nathoo, E Chidziva, L Atwine, N Ramsagar, A Liberty, P Amuge, E Kaudha, A Nanduudu, R Mngqibisa, R Mosia, MF Cotton, TR Cressey, T Puthanakit, A Compagnucci, C Giaquinto, P Rojo, D Ford, DM Gibb, A Turkova, the ODYSSEY trial team

Published in: IAS 2021

 

Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial

2021

Authors: C. Kityo, E. White, A. Turkova, H.A Mujuru, I. Nankya, B. Wynne, S. Ali, A. Kekitiinwa, A. Lugemwa, E. Kaudha, A. Liberty, H. Cassim, M. Archary, M. Cotton, L. Barlow-Mosha, T.R Cressey, C. Ngampiyasakul, U. Srirompotong, O. Behuhuma, Y. Saidi, A. Bamford, R. Kobbe, P. Rojo, C. Giaquinto, D. Gibb, D. Ford

Published in: IAS 2021

 

Abstract

Background: ODYSSEY demonstrated superiority of dolutegravir (DTG) based ART versus standard-of-care (SOC) in children ≥14kg starting first- or second-line.

Increasing burden of viral bronchiolitis in the pediatric intensive care unit; an observational study

2021

Authors: RS. Linssen, AC. Teirlinck, Mv Boven, D Biarent, L Stona, A Amigoni, RI. Comoretto, S Leteurtre , A Bruandet, GK. Bentsen, IM Drage, X Wang, H Campbell, JBM. van Woensel, L Bont, RA. Bem

Published in: Journal of critical care

 

Abstract

Purpose: Viral bronchiolitis is a major cause of pediatric intensive care unit (PICU) admission.

1234567891011